Nautilus Biotechnology (NASDAQ:NAUT) Research Coverage Started at Leerink Partners
Leerink Partners started coverage on shares of Nautilus Biotechnology (NASDAQ:NAUT – Free Report) in a research note released on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $4.00 price target on the stock. Separately, Weiss Ratings downgraded Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research […]
12 Sep 02:37 · The Cerbat Gem